Objective-(1) To determine the pharmacokinetics, safety, and tolerability of a novel, controlled release oral formulation of α-lipoic acid (LA), (2) To investigate whether sustaining the concentration of LA in plasma would have a beneficial effect on glycemic control in patients with type 2 diabetes.
Introduction
α-Lipoic acid (LA) is an eight-carbon fatty acid that is synthesized in trace quantities in organisms ranging from bacteria to man (1) (2) (3) . LA functions naturally as a cofactor in several mitochondrial enzyme complexes responsible for oxidative glucose metabolism and cellular energy production (4;5). When administered exogenously, LA and its reduced form, dihydrolipoic acid (DHLA), act as multifunctional antioxidants (1;2) . LA has been prescribed in Germany for over thirty years for the treatment of diabetes-induced neuropathy (6) (7) (8) , and results from several recent controlled clinical studies indicate that this compound is safe, well-tolerated, and efficacious (8) .
In addition to the beneficial effects of LA on diabetes-induced neuropathy, several clinical studies point to an improvement in insulin sensitivity and wholebody glucose metabolism in patients with Type 2 diabetes following continuous intravenous (i.v.) infusion of LA (9) (10) (11) . It has been reported that i.v. infusion of LA markedly increases insulin-mediated glucose disposal (~30-50%) (9;10), whereas oral administration of LA has only marginal effects (<20%) (12;13) . Furthermore, the currently available oral forms of LA have not been reported to reduce glucose, fructosamine, or HbA 1c levels in patients with diabetes (12) (13) (14) (15) (16) (17) (18) (19) (20) . It is possible that this limitation of orally administered LA might be a function of its abbreviated duration in plasma (compared to i.v. LA), resulting from extensive first-pass metabolism (> 50%) and/or short plasma half-life (<0.5 h) (21) . In this regard, the superior ability of i.v. LA to improve insulin sensitivity might be due to the ability of i.v. adminstration to achieve a higher plasma concentration of LA, and/or to maintain it for a longer duration. A continuous infusion (over 20 minutes) of 200 mg LA resulted in a peak plasma level of approximately 8 µg/ml, and detectable levels were still observed six hours after the start of infusion (21) .
In contrast, oral administration of a 200 mg tablet resulted in a peak plasma level of approximately 0.66 µg/ml, which returned baseline < 3 hours after dosing (22).
In this preliminary, open-label study, we evaluated the pharmacokinetics, safety, and tolerability of a novel, controlled release oral formulation of α-lipoic acid (LA). This formulation was designed to maintain the plasma concentration of LA over time using controlled release drug delivery technology (polymeric cellulose resins). In addition, we also investigated whether this agent would result in a beneficial impact on glucose control in patients with Type 2 diabetes. We report here that this agent was safe, well-tolerated, and significantly reduced plasma fructosamine in patients with type 2 diabetes. The mean HbA 1c level (%) was 8.2 ± 1.5. Following a run-in period of two weeks, patients received 12 weeks of active treatment of CRLA. The agent was administered as 900 mg daily (2 x 300 mg tablets 30 minutes before breakfast and 1 x 300 tablet 30 minutes before dinner) for 6 weeks, followed by 1200 mg daily (2 x 300 mg tablets before breakfast and 1 x 300 tablet before both lunch and dinner) for 6 weeks. A three-week washout period followed active treatment.
Materials and Methods

Subjects and Study
Patients were monitored on a regular basis for glucose and lipid control, liver enzymes, along with other clinical markers including physical examination, vital signs, and adverse experience queries.
Six patients were not included in the final statistical analyses. These exclusions were made blinded to results. Four patients were excluded due to their recurring failure (≥ 3 instances) to adhere to their allocated diets. Diet was judged initially acceptable if it provided sufficient caloric intake to maintain body weight, and caloric distribution approximating the following: 50-60% carbohydrate, <30% fat, and 15-20% protein. Diets were evaluated at the beginning of the run-in phase, and monitored on a regular basis throughout the study. Failure to adhere was judged to have occurred if carbohydrate, fat, and/or total caloric intake grossly exceeded (>150%) a patient's usual weekly intake based on patient interviews. One patient was excluded due to premature withdrawal due to a recurring illness not considered related to study medication, and one patient was excluded from analyses due to repeated missed laboratory values. Glucose, HbA 1C , clinical chemistry and hematology assays, and lipid panels were performed in the clinical laboratory at Seton Medical Center.
Fructosamine and C-peptide assays were performed at Specialty Laboratories, Inc. (Santa Monica, CA). Intra-and inter-assay coefficients of variation were ≤ 5%. 
Results
Clinical Trial 1: Pharmacokinetic Study in Healthy Individuals
The mean plasma concentration profile of LA following oral dosing is shown in Figure 1 
Clinical Trial 2: Safety and Tolerability Study in Individuals with Type 2 Diabetes
There were no significant side effects reported following the administration of CRLA to patients with type 2 diabetes. Two patients reported a slight metallic taste following the dose increase to 1200 mg/day, but this effect was transient and did not require either individual to withdraw from the study. There were no significant changes in liver enzymes, liver or kidney function, or hematological profiles (data not shown). Thus, CRLA was well tolerated and safe at daily doses of 900 mg for six weeks followed by 1200 mg for six weeks.
CRLA exhibited a significant effect with regard to the reduction of plasma fructosamine. At baseline, the mean plasma fructosamine was 313 ± 48.6 µM (SEM; n = 15), and after six weeks of treatment was 307 ± 43.0 µM (P < 0.465; Figure 2 ). At this point, the dose of CRLA was increased to 1200 mg/day. After three weeks on the higher dose, the mean plasma fructosamine was reduced to 275 ± 42.6 µM (P < 0.033; Figure 2 ). At the completion of active treatment (twelve weeks), the mean plasma fructosamine was 283 ± 48.7 µM (P < 0.05; Figure 2 ), corresponding to an overall mean decrease from baseline of 30.1 ± 9.7 µM. After a three-week washout, the mean plasma fructosamine rose to 304 ± 56.8 µM (P < 0.454; Figure 2 ). No significant changes were observed in either fasting plasma glucose or HbA 1c . At baseline, fasting plasma glucose and HbA 1c were 157 ± 34 mg/dl and 8.2 ± 1.5 % (mean ± SD), respectively. At the completion of active treatment (twelve weeks), fasting plasma glucose and HbA 1c were 168 ± 36.5 mg/dl (P < 0.37) and 8.2 ± 0.84 % (P < 0.94), respectively. A trend toward a reduction in C-peptide was observed. At baseline, the mean plasma C-peptide was 5.0 ± 3.8 ng/ml and after twelve weeks of treatment fell to 4.2 ± 2.8 ng/ml ( Table 1 ). The overall mean decease from baseline was 0.84 ± 0.72 ng/ml (p < 0.26). No significant changes were observed in triglycerides, total, high-density, or low-density lipoprotein cholesterol, body weight, or body mass index following treatment (Table 1) .
Discussion
This is the first report of the development, use, and clinical assessment of a controlled release formulation of LA. This approach was initiated and pursued to test the hypothesis that limitations of the current oral QRLA with respect to effects on insulin sensitivity and metabolic control (compared to i.v. infusion) might be a function of the abbreviated duration for which LA is maintained in plasma.
Using controlled release drug delivery technology, the T max of LA was increased approximately 2.5-fold (1.25 hours for CRLA vs. 0.5 hours for QRLA), reflecting the slower release of LA from the formulation matrix. Importantly, the plasma concentration of LA remained level for several hours in the controlled release formulation, whereas it fell more rapidly when delivered in quick release capsules. The therapeutic implication of maintaining LA in plasma for a longer duration than can be achieved with typical oral QRLA is suggested by the clinical benefit of LA on whole-body insulin sensitivity when administered by i.v. infusion (9) (10) (11) .
CRLA exhibited decreased a C max compared to QRLA. This is also a formulation effect, since controlled release formulations are designed to reduce C max (25). The reason for the observed decrease in overall bioavailability of the CRLA (judged by lower a AUC) compared to QRLA is unknown. It is possible that there was a difference in the rate or extent of absorption of the two formulations.
It cannot be determined from this study if the controlled release matrix constituents affected the absorption of LA. Another possibility is that the slower release of the CRLA promoted more extensive first-pass hepatic metabolism.
The T 1/2 value was not significantly different between the two formulations. This suggests that the increased duration of CRLA was due to controlled plasma delivery as opposed to a decrease in the actual rate of elimination. The T 1/2 of the QRLA capsules used here is in good agreement with that reported for entericcoated tablets (21) .
At doses of 900 mg/day for six weeks followed by 1200 mg/day for six weeks, CRLA was well tolerated, and did not produce any significant changes in liver enzymes, liver or kidney function, or hematological profiles. No serious side effects were observed. These results are in good agreement with the long history of safety and tolerability of LA, whether administered by i.v. infusion or orally (8) .
It cannot be determined from this study whether CRLA interacted with other medications, although no subject required an adjustment in dose of their concurrent medication. To assess the potential for drug-drug interaction between CRLA and other anti-diabetic medications, more systematic studies would be required. A recent study has found that co-administration of single oral doses of QRLA and glibenclamide, or QRLA and acarbose did not result in drug-drug interactions (26).
With respect to glycemic control, CRLA produced a reduction of plasma fructosamine, an effect that was statistically significant at weeks nine and twelve. This corresponds to weeks three and six following dose escalation to 1200 mg CRLA per day. At the completion of active treatment, the decrease in fructosamine from baseline was 30 µm, corresponding to an approximate 10% overall reduction. Following a three-week washout period, fructosamine increased towards the baseline value. This finding provides preliminary support for our hypothesis that maintaining the level of LA in plasma over time might result in an overall improvement in glycemic control.
The decrease in fructosamine was observed in the absence of a reduction in fasting plasma glucose. The reason for this is unknown, and will have to be addressed in future studies in which post-prandial glucose levels are also taken.
The decrease in fructosamine was also observed in the absence of a reduction in baseline. Statistical significance was accepted at P < 0.05. 
